

The performance of an aseptic process is challenging, but technical advances in aseptic processing, including improved automation, use of isolator systems, formulations to include antimicrobial effects, and combinations of limited sterilization with aseptic processing, have decreased the risk of contamination. Therefore, the successes realized should encourage continued efforts to improve the assurance of sterility achievable with aseptic processing. The importance of this is that for many drug solutions and essentially all biopharmaceutical products, aseptic processing is the only method that can be considered for preparing a sterile product.

Interaction among environmental conditions, the constituents in the closure, and the product may result in undesirable closure changes such as increased brittleness or stickiness, which may cause loss of container–closure seal integrity. Thus, shelf life integrity is an important consideration in closure selection and evaluation.

The assessment of aseptic-processing performance is based on the contamination rate resulting from periodic process simulations using media filling instead of product filling of containers. A contamination rate no greater than 0.1% at 95% confidence has generally been considered as indicative of satisfactory performance in the industry. However, with current advances in aseptic-processing capabilities, lower contamination rates may be achievable.

Radiation sterilization, as mentioned, is gaining some momentum as an alternative terminal sterilization method. There has been limited understanding of the molecular transformations that may occur in drug molecules and excipients under exposure to the high-energy gamma radiation levels of the process. However, lower energy beta particle (electron beam) radiation has seen some success. There is still significant research that must be accomplished before radiation sterilization is used as a terminal sterilization process. The use of radiation for the sterilization of materials such as plastic medical devices is well established.

Dry heat sterilization may be employed for a few dry solids that are not affected adversely by the high temperatures and for the relatively long heating period required. This method is applied most effectively to the sterilization of glassware and metalware. After sterilization, the equipment will be sterile, dry, and, if the sterilization period is long enough, pyrogen free.

Saturated steam under pressure (autoclaving) is the most commonly used and the most effective method for the sterilization of aqueous liquids or substances that can be reached or penetrated by steam. A survival probability of at least 10^{-6} is readily achievable with terminal autoclaving of a thermally stable product. However, it needs to be noted that for terminal sterilization, the assurance of sterility is based on an evaluation of the lethality of the process, that is, of the probable number of viable microorganisms remaining in product units. However, for aseptic processing, where the components used have been sterilized separately by validated processes and aseptically put together, the level of sterility assurance is based on an evaluation of the *probable* number of product units that were contaminated during the process.

Because the temperature employed in an autoclave is lower than that for dry heat sterilization, equipment made of materials such as rubber and polypropylene may be sterilized if the time and temperature are controlled carefully. As mentioned previously, some injections will be affected adversely by the elevated temperature required for autoclaving. For some products, such as Dextrose Injection, a shortened cycle using an autoclave designed to permit a rapid temperature rise and rapid cooling with water spray or other cooling methods will make it possible to use this method. It is ineffective in anhydrous conditions, such as within a sealed ampoule containing a dry solid or an anhydrous oil. Other products that will not withstand autoclaving temperatures may withstand marginal thermal methods, such as tyndallization or pasteurization. This describes a practice where a product is heated to approximately 100°C in order to activate any bacterial spores present to revert to their vegetative forms, thus much easier to destroy. A second 100°C exposure will destroy the vegetative form and a third 100°C exposure will add assurance that complete bacterial destruction has occurred. Theoretically, this practice could be applied as a terminal sterilization method for products containing heat sensitive active pharmaceutical ingredients. However, since the process cannot be validated using conventional biological indicators (remember, BIs are bacterial spores), it is not considered as a viable option for terminal sterilization.